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Abstract
Myofibroblasts (Mfs) that persist in a healing wound promote extracellular matrix (ECM) accumulation and excessive tissue
contraction. Increased levels of integrin avb5 promote the Mf phenotype and other fibrotic markers. Previously we reported
that maintaining uPA (urokinase plasminogen activator) bound to its cell-surface receptor, uPAR prevented TGFb-induced
Mf differentiation. We now demonstrate that uPA/uPAR controls integrin b5 protein levels and in turn, the Mf phenotype.
When cell-surface uPA was increased, integrin b5 levels were reduced (61%). In contrast, when uPA/uPAR was silenced,
integrin b5 total and cell-surface levels were increased (2–4 fold). Integrin b5 accumulation resulted from a significant
decrease in b5 ubiquitination leading to a decrease in the degradation rate of internalized b5. uPA-silencing also induced a-
SMA stress fiber organization in cells that were seeded on collagen, increased cell area (1.7 fold), and increased integrin b1
binding to the collagen matrix, with reduced activation of b1. Elevated cell-surface integrin b5 was necessary for these
changes after uPA-silencing since blocking avb5 function reversed these effects. Our data support a novel mechanism by
which downregulation of uPA/uPAR results in increased integrin avb5 cell-surface protein levels that regulate the activity of
b1 integrins, promoting characteristics of the persistent Mf.
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Introduction
Myofibroblasts (Mfs) promote normal healing and wound
closure but eventually die by apoptosis [1]. Deregulation of this
process leading to the persistence of Mfs contributes to fibrosis and
scarring by overproduction of extracellular matrix (ECM) and
excessive tissue contraction. Persistent Mfs participate in an
autocrine loop of TGFb activation that leads to accumulation of
ECM and stabilization of the Mf phenotype that promotes fibrotic
disease [2,3,4].
Several factors are known to regulate differentiation of fibroblast
to Mfs. Our current work is focused on the contribution of the
uPA pathway to this process. uPA is an extracellular serine
protease that binds to its receptor, uPAR, and converts
plasminogen into plasmin at the cell-matrix interface. In addition
to the generation of plasmin, uPA binding to uPAR stimulates
uPAR’s interaction with integral membrane proteins, such as
integrins, which modulate cytoskeletal organization and cell
migration [5]. In our previous work, we showed that maintaining
full-length uPAR, consisting of 3 domains, (D1D2D3) on the cell-
surface, as opposed to cleaved uPAR (D2D3), prevented Mf
differentiation [6]. This finding suggested that proper regulation of
uPAR is an important part of the normal differentiation program.
Our goal in the current work was to understand the mechanism by
which full-length uPAR affects Mf differentiation.
Full-length uPAR binds uPA, integrins, among them avb3 and
avb5 integrins [7,8], and the matrix molecule vitronectin; cleaved
uPAR loses the ability to participate in these interactions [9,10].
Over-expression of cleaved uPAR (D2D3) in cells that lack
endogenous uPAR, led to an increase in integrin-mediated cell
adhesion, suggesting that the D1 domain of uPAR plays a role in
regulating the adhesive functions of integrins [9]. Enhanced cell
adhesion promotes Mf differentiation, as stabilized cell attachment
to ECM generates the cellular tension required for assembly of the
Mf’s characteristic alpha-Smooth Muscle Actin (a-SMA) stress
fibers [11,12]. Thus, our finding that, compared to fibroblasts, Mfs
have reduced levels of full-length uPAR [6] suggests that Mf
integrins may no longer be regulated by uPAR, leading to greater
cell adhesion.
Integrin avb5 is integral to the Mf phenotype and related TGFb
activity. avb5 expression and TGFb activity are upregulated in
Mfs derived from fibrotic, sclerodermal tissue. Furthermore,
treatment of these sclerodermal fibroblasts with anti-avb5
antibodies reduces TGFb activity and Mf differentiation [13,14].
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33915Finally, a mechanism by which avb5 activates TGFb was recently
described wherein avb5 binds to the RGD sequence in the LAP-
TGFb and the mechanical force generated by integrin-mediated
Mf contraction releases active TGFb [15]. Together, these data
suggest that increased levels of avb5 contribute to persistent Mfs
and fibrotic disease. Since uPAR cleavage leads to an increase in
integrin-mediated cell adhesion, and the cleavage and subsequent
downregulation of uPAR correlates with Mf differentiation (a cell
phenotype that is dependant upon increased cell adhesion) [11],
we investigated whether Mfs are regulated by uPA/uPAR’s
control of integrin avb5. Here we report that uPA bound to uPAR
regulates integrin b5 levels; in the absence of uPA, ubiquitination
and degradation of internalized b5 is drastically reduced leading to
a significant increase of cell-surface b5, which promotes integrin
b1 binding to a collagen matrix generating a Mf-like phenotype.
Defects in protein degradation play an important role in many
diseases [16,17,18]. However, protein degradation (ubiquitin)
pathways have not been widely considered in generation of Mfs
or in the pathogenesis of fibrotic healing in general. Our study
may open the way to novel therapeutic approaches for the
prevention of fibrotic disease.
Results
Integrin avb5 expression is uniquely associated with the
Mf phenotype
To demonstrate that avb5 expression and function is key to
maintaining the TGFb-induced Mf phenotype, we treated human
primary corneal fibroblasts (HCFs) with either TGFb1o ra sa
comparison, FGF-2 plus heparin a combination that promotes the
fibroblast phenotype [19], each for 72 hours prior to analysis. All
experiments were performed under defined conditions (supple-
mented-serum free conditions (SSFM, see methods) on collagen
type I). Surface expression of the integrin b5 was assessed in two
distinct manners, indirect immunostaining of live cells followed by
quantitative flow cytometry or immunoblotting of biotin labeled
surface proteins. To provide a comparison to levels of integrin b5,
we also measured cell-surface levels of integrin b3. By flow
cytometry, the TGFb1 treatment resulted in a cell-surface integrin
b5 level that was 1.56+/2.01 fold higher, *p value,.05 than that
observed in the presence of FGF-2 (Figure 1A). Unlike the case for
b5, the expression of b3 was not affected by the difference in
growth factor exposure (Figure 1A, right). The cell-surface
biotinylation approach yielded a more extreme difference in the
degree of b5 expression (Figure 1B). As in the flow cytometry case,
the difference in growth factor exposure did not affect the amounts
of b3. Qualitatively the flow data and cell-surface IP both show
that TGFb1 treatment leads to an increase in cell-surface integrin
b5. The observed quantitative difference in integrin expression is
most likely caused by the vast difference in methodology; prior to
immunoblotting cells have to be solubilized, a process that is likely
to recover most of the surface integrins. In contrast, flow cytometry
requires that the strongly adherent fibroblasts be first detached.
Previous studies have demonstrated that cell detachment leads to
the internalization of multiple plasma membrane proteins
including cell-surface [20,21] and thus may reduce cell-surface
staining.
TGFb induction of b5 expression is time dependent
Our previous work showed that in cultured HCFs treated for 7
days with TGFb1, uPAR is cleaved into its D2D3 form and by day
7, uPAR protein expression is nearly absent on the resultant Mfs
[6]. Since b5 is associated with the TGFb-induced Mf phenotype
we investigated whether an increase in b5 gene expression in
response to TGFb1 treatment correlated with the enhancement of
Mf differentiation; integrin b3 and uPAR served as controls. Real
time PCR was performed on mRNA isolated at Day 1 and Day 7
of TGFb1 treatment. While b5 mRNA expression increased by
100% on day 7 of treatment (fully differentiated Mfs), the b3
decreased by 80% and uPAR decreased by 56% (Figure 1C). To
assess the importance of b5 to Mf differentiation, we blocked
functional interactions of integrin b5 with an antibody and
measured the impact of this treatment on a-SMA stress fiber
organization, a key marker of the Mf. HCFs were differentiated
into Mfs by treating with 1 ng/ml TGFb1 for 48 hours and then
incubated for 24 hours with a blocking anti-avb5 antibody.
Compared to IgG treated cells, cells treated with anti-avb5
disrupted a-SMA stress fibers (Figure 1D), although the number of
cells adhering to collagen was not reduced. (The affect of this
antibody on cell adhesion was quantified and will be discussed
later.) These data demonstrate that, similar to the previously
reported effect in sclerodermal fibroblasts [13] blockade of b5
decreases the TGFb-induced indicators of Mf differentiation. Of
significance is that with TGFb1 treatment, uPAR and b5 have
reciprocal expression patterns (Figure 1C). This led us to
investigate whether cell-surface uPA and/or uPAR regulates b5
levels. For the remainder of the experiments, TGFb was not
added.
uPA and uPAR regulate integrin b5 protein levels
Full-length uPAR but not cleaved uPAR on the cell-surface
binds to extracelluar uPA. Thus over-expressing a form of uPAR
that cannot be cleaved (non-cleavable uPAR) will maintain both
full-length uPAR and uPA on the cell-surface. To determine if an
increase in uPA bound to uPAR on the cell surface regulates the
protein levels of integrin b5, HCFs were transfected with non-
cleavable uPAR cDNA (uPAR NC) [22] or vector alone (control).
Compared to control, over-expression of uPAR NC (confirmed by
real time PCR, data not shown) reduced b5 levels by an average
61% (Figure 2A). uPAR NC expression led to a 43% increase in
cell-associated uPA activity, (right of the Western blot in
Figure 2A). Thus there was less b5 when uPA was maintained
on the cell-surface.
To test the effect of uPA/uPAR downregulation on avb5 levels,
HCFs were transfected with siRNA to uPA, uPAR or a non-
targeting control. siRNA knock-down of uPA and uPAR was
confirmed by Western blotting. In cells in which uPA was silenced,
the total b5 protein levels were increased from approximately 2 to
4-fold (Figure 2B); (the range presumably reflects the variation in
the primary fibroblasts obtained from individual donors). In cells
with knocked-down uPAR, the b5 levels were increased by
approximately 2-fold (Figure 2C). The fact that uPAR knockdown
also lead to an increase in b5 levels suggests that the presence of
uPA without uPAR (confirmed in Figure 2D) does not regulate b5.
Thus, as would be expected, uPA binding to uPAR appears to be
required for its regulation of b5.
Next we tested whether the increase in b5 protein in uPA-
silenced cells was reflected in increased cell-surface accumulation
of the integrin. Cells were transfected with uPA-siRNA or control
siRNA, and 24 hrs later, cells were analyzed by flow cytometry.
Here we demonstrate that uPA-silencing increased b5 on the cell-
surface by 1.22+/2.07 fold, **p value,.01 (Figure 2E).These data
were supported by cell-surface biotinylation. Biotinylated lysates
were immunoprecipitated with streptavidin beads followed by
Western blot for b5. Results shown in Figure 2F demonstrate that
uPA-silencing leads to an average 3.1-fold increase in cell-surface
avb5 using this technique. Again, similar to Figure 1, cell-surface
biotinylation reveals greater differences between samples, likely
uPA Regulates Integrin avb5
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detection of integrins on the cell surface as stated above. Our
demonstration that cell-surface integrin b5 is increased after uPA-
silencing is supported by the fact that b5 function is also increased.
Specifically, binding of integrin b5 with its primary ligand,
vitronectin (VN) and cell adhesion to VN were both significantly
increased after uPA-silencing (Figure 2G). After transfection with
uPA and control siRNA, cells were seeded on VN for 24 hrs and
treated with a cleavable cross-linking reagent, followed by removal
of cells with a buffer containing 0.1% SDS. Cell membrane
proteins that were cross-linked to matrix were cleaved and equal
amounts of protein in each sample were analyzed for b5 content
Figure 1. Integrin b5 protein expression is increased on TGFb-induced Mfs. HCFs were treated with TGFb1 or FGF-2 plus heparin for
72 hours and analyzed for b5 and b3 cell-surface expression. (A) Flow cytometry (B) Cell-surface biotinylation; lysates were immunoprecipitated (IP)
with antibody against integrin b5, separated by SDS-PAGE and probed with streptavidin-HRP to detect biotinylated proteins. Bands were identified
by molecular weight. GAPDH indicates equal protein input for IP. Quantification of the b5 band relative to GAPDH input control is shown. (C) Real-
time PCR for b5, b3, and uPAR at Day 1 and Day 7 after TGFb1 treatment. *p value,0.05 for gene expression between Day 1 and Day 7 for each. (D)
HCF were stimulated with TGFb for 48 hours to initiate Mf differentiation and then treated with anti-avb5 function blocking antibodies or IgG
controls overnight. Cells were fixed and immunostained for a-Smooth Muscle Actin (a-SMA). N=3–5 for each experiment.
doi:10.1371/journal.pone.0033915.g001
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33915Figure 2. uPA expression controls integrin b5 levels. (A) HCFs were transfected with a non-cleavable uPAR mutant cDNA (uPAR NC) or control
vector. After 48 hours, cells were lysed and subjected to Western blot analysis for integrin b5. GAPDH indicates equal loading. Cell associated PA
activity was measured colorimetrically by adding plasminogen and a chromogenic substrate for plasmin to cell lysates. Cell associated PA activity is
shown to the right. *p value,0.05. HCF were transfected with (B) uPA siRNA or non-targeting siRNA control or (C) uPAR siRNA or non-targeting siRNA
control. After 24 hours, lysates were Western blotted for b5 and uPA or uPAR to confirm knockdown. (D) HCF were transfected with uPAR siRNA, uPA
siRNA, or control siRNA. After 24 hours, lysates were Western blotted for uPA. The data in (D) demonstrate that uPA is still expressed after uPAR
silencing with uPAR siRNA. GAPDH indicates equal loading. (E–G) HCFs were transfected with uPA siRNA or control siRNA. (E) Flow cytometry. (F) Cell-
surface biotinylation: After 24 hours, HCFs were cell-surface biotinylated before lysing and IP with streptavidin-HRP beads followed by Western for b5.
GAPDH indicates equal input of protein for IP. (G) Integrin b5 bound to vitronectin (VN), top: After 24 hours, HCFs were treated with a cleavable cross-
linker and cells were removed by lysis with 0.1% SDS. Next, the cross-linker was cleaved, releasing VN-bound proteins. This fraction was concentrated
equal protein was Western blotted for b5. Bottom: Cell adhesion on VN: 24 hours after transfection, cells were detached and plated on VN for another
24 hours. Cells were fixed, stained with DAPI and counted. **p value,0.01. N=3–7 for each experiment.
doi:10.1371/journal.pone.0033915.g002
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confirmed that cells were not present in the protein fraction that
was released from the matrix. As expected, based on the flow
cytometry and cell-surface biotinylation experiments, the associ-
ation of integrin b5 with VN is increased in uPA-silenced cells
(Figure 2G, top). Next we performed a typical adhesion assay on
VN after uPA-silencing. Cells were transfection with uPA siRNA
or control and seeded onto collagen. After 24 hours cells were
detached and seeded on VN for 1 hour. In support of our finding
that differences by flow cytometry were difficult to observe directly
after cell detachment, uPA-silenced cells plated on VN for 1 hour
demonstrated only a small increase in cell adhesion to VN (data
not shown). However, when the transfected cells were seeded on
VN and incubated for 24 hours, cell adhesion on VN, was 2.4-fold
higher in uPA-silenced cells than in control (Figure 2G, bottom).
Together these experiments on VN reveal that the increased cell
surface b5 after uPA-silencing results in a functional increase in
ligand binding.
uPA-mediated degradation of internalized b5 controls b5
protein levels
To determine whether uPA exerts transcriptional control on
integrin b5 gene expression, RNA extracted from uPA-silenced
cells and controls at 6 and 24 hrs was evaluated by real time PCR;
b5 expression is not increased after uPA-silencing (Figure 3A).
These data indicate that the increase in b5 protein levels is due to
translational or post-translational control.
Human corneal cells in serum-free medium, in which our
experiments are performed, do not produce plasminogen [23].
However, since the HCFs are passaged in serum-containing
medium (with plasminogen), and since plasminogen binds to the
cell-surface, we wanted to exclude the possibility that avb5 was
increased after uPA-silencing only because uPA-generated plasmin
on the cell-surface was not present to degrade integrin b5. To test
this, cell-surface uPA activity was increased with non-cleavable
uPAR (as in Figure 2) and then plasmin was blocked with a-2-anti-
plasmin (AP) [24]. As expected, NC-uPAR over-expression led to
a reduction in b5 compared to control (Figure 3B, lanes 1 and 3).
Treating cells with a-2-anti-plasmin did not affect the protein
levels of b5 suggesting that plasmin is not involved in the observed
decrease of this integrin (Figure 3B, lane 2). Furthermore, it is
unlikely that uPA is directly degrading b5. There were no b5-
derived cleavage products on Western blots (probed with a
polyclonal anti-b5 antibody) as has been reported for uPA-
mediated cleavage of integrin a6 [25]. In addition, treatment with
uPA did not produce any b5 degradation products, even if the cells
were first stripped of endogenous uPA (data not shown).
Since cell-surface b5 was increased after uPA-silencing
(Figure 2), we tested whether uPA-silencing reduced b5 internal-
ization. To address this question, HCFs were transfected with uPA
or control siRNA and after 24 hrs cell-surface biotinylated at 4uC
and then warmed to 37uC to stimulate endocytosis. After
30 minutes, the remaining cell-surface biotin was cleaved. Cells
were then lysed and immunoprecipitated with streptavidin beads
and Western blotted for b5. Contrary to expectation, we found an
average 2.5-fold increase in internalized b5 in uPA-silenced cells
than in control cells (Figure 3C), suggesting that inhibition of b5
internalization does not contribute to the accumulation of b5. The
build-up of b5 (cell-surface and total) upon uPA-silencing, which
occurs without a defect in b5 internalization, suggests that
internalized b5 is not being degraded and may continue to be
recycled back to the cell-surface. Thus, we asked if the degradation
rate of internalized b5 was affected by uPA-silencing. HCFs were
transfected with uPA siRNA or control siRNA and after 24 hours
the cells were cell-surface biotinylated for 30 minutes at 4uC and
then returned to 37uC for the indicated times. Strikingly, we found
that compared to control siRNA, b5 degradation was inhibited by
an average of 66% in uPA-silenced cells at 24 hrs (Figure 3D).
This time scale for degradation of integrins is similar to what has
been previously described [26]. Because of the considerable
reduction in the b5 degradation rate, we asked whether uPA-
silencing reduced b5 ubiquitination. In Figure 3E, we show that
there is an average 56% decrease in ubiquitin labeling of b5 after
uPA-silencing, suggesting that it is an important contributor to b5
accumulation. Finally, to further confirm that b5 ubiquitination
influences the levels of b5 and to determine if integrin b5i s
degraded in the endosomal pathway, we transfected siRNAs to
endosomal ESCRT proteins, tsg101 and hrs. ESCRT proteins
play a role in sorting ubiquitinated proteins through the
endosomal pathway [27]. Depletion of these two ESCRT subunits
produces more dramatic effects on the accumulation of ubiquiti-
nated proteins in the endosomal pathway than a single depletion
by preventing cargo from reaching the lysosome for degradation
[28]. In Figure 3F we demonstrate that simultaneous silencing of
tsg101 and hrs results in a 2.4 fold increase in the levels of integrin
b5. An 85% knock down of tsg101 and 42% knockdown of hrs was
confirmed by RT-PCR. Furthermore, we confirmed that b5 gene
expression was not increased by ESCRT knockdown even though
protein levels are elevated. Together these data show that uPA
regulates b5 ubiquitination and that b5 ubiquitination is necessary
for its processing through the endosomal pathway.
uPA deficiency has Mfs characteristics; increased cell area
and a-SMA stress fiber organization
As previously stated, downregulation of uPAR (and therefore
uPA/uPAR binding) and increased b5 is associated with the Mf
phenotype, suggesting that uPA/uPAR-mediated control of b5
may play a role in Mf differentiation. Although the primary ligand
of avb5 is VN, in vivo, collagen is a major constituent of fibrotic
tissue. For this reason, all of our experiments were performed on
collagen. To determine if uPA-silencing promoted fibrotic
phenotypic changes, uPA-silenced were immunostained for a-
SMA containing stress fibers, a key marker of Mf differentiation.
In Figure 4A, we demonstrate that uPA-silencing generates large
cells, and approximately 19%+/25% of HCFs transfected with
uPA siRNA had immunodetectable a-SMA in stress fibers
whereas in control HCFs there were none. (Images from two
separate experiments are shown). Metamorph analysis showed the
area of uPA-deficient cells was 1.7-fold larger on average than
control cells (Figure 4B). Parallel studies performed with uPAR
siRNA showed similar but a slightly lesser increase in cell area
(1.4-fold +/20.14, ***p value=,.001, data not shown).
Earlier studies reported that avb5 on Mfs plays a role in
activating TGFb [13,15,29]. Since we detected elevated levels of
b5 after uPA-silencing we investigated whether this was accom-
panied by an increase in TGFb activity. Using a luciferase
bioassay [30] and an ELISA assay for active TGFb, we were
surprised to find that there was no difference in the amount of
active TGFb between uPA-silenced cells and control (24 hrs after
transfection) (data not shown). (This was also true when the cells
were assayed in serum-containing medium.) Western blots showed
approximately equal expression of a-SMA in uPA-silenced cells
versus control (Figure 4C) but only uPA-silencing generated
enlarged cells with a-SMA organized in stress fibers. Together our
data suggest that after uPA-silencing the cells exhibit increased
cell/matrix tension, which induces cell spreading and a-SMA
stress fiber organization without further increase in active TGFb.
Wipff et al. demonstrated that Mf-generated mechanical tension
uPA Regulates Integrin avb5
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e33915Figure 3. uPA-silencing reduces the degradation of internalized b5. (A) Gene expression: HCFs were transfected with uPA siRNA or control
siRNA and lysed for RNA or protein at 6 hrs or 24 hours. (top) Real-time PCR for b5 demonstrates no increase in b5 gene expression. (bottom)
Western blot for uPA confirms uPA knockdown. (B) Plasmin activity: HCFs were transfected with non-cleavable uPAR (NC) or control vector (C). NC-
uPAR transfected cells were either untreated (2) or incubated with a-2-anti-plasmin (AP). (C–E) HCFs were transfected with either uPA siRNA or
control siRNA. (C) Internalization Assay: HCFs were cell-surface biotinylated at 4uC. Cells were warmed to 37uC for 30 minutes and the remaining cell-
surface biotin was cleaved. Cells were lysed and biotin-containing proteins were precipitated with streptavidin beads. Integrin b5 was detected by
Western blot. (D) Degradation Assay: HCFs were cell-surface biotinylated at 4uC. Cells were warmed to 37uC for the indicated time points before
lysing. Biotin-containing proteins were precipitated with streptavaidin beads. Integrin b5 was detected by Western blot. Numbers from densitometry
of b5 bands were equalized to GAPDH and graphed as percent remaining compared to time zero. (E) Ubiquitination of b5: HCFs were IPed with
antibody to ubiquitin (mono or poly ubiquitin, FK2 antibody) and integrin b5 was detected by Western blot. F. HCFs were transfected with siRNA to
tsg101 and hrs ESCRT subunits. After 48 hours cells were lysed and Western blotted for b5. GAPDH indicates equal loading (A, B, and F) or equal
protein input for IP (C and E). Knock down of hrs and tsg101 together (ESCRT) was validated by RT-PCR. b5 expression after ESCRT knockdown is also
shown. N=3 for each experiment.
doi:10.1371/journal.pone.0033915.g003
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presence of protease inhibitors [15]. However it is unknown what
the role of cell surface uPA protein, uPA/uPAR binding, and
uPA/integrin b5 binding [31,32] is in this type of TGFb
activation. One interpretation of our data is that avb5-mediated
TGFb activation requires uPA. Next we used a avb5 blocking
antibody to determine if the phenotype changes induced by uPA-
silencing are mediated by avb5.
avb5 blocking antibody reverses the phenotypic effects
of uPA siRNA
If the increase in cell area, a-SMA organization into stress fibers
observed after uPA-silencing in Figure 4 are due to an increase in
integrin b5 levels, we would expect these to be eliminated by
blocking avb5 function. uPA-silenced cells were treated with
blocking avb5 antibody or matched IgG control. Figure 5A shows
that, compared to control IgG, the avb5 blocking antibody
prevented the enlargement of the cell area and formation of a-
SMA stress fibers in uPA-silenced cells. (Images from two
experiments are shown). Metamorph analysis demonstrated that
avb5-blocked cells were on average 50% smaller than control IgG
treated cells (Figure 5B), and similar to the non-uPA-silenced cells
(Figure 4B).
Integrin b1 expression levels and activity are mediated
by uPA
Since b5 integrin is a VN-binding integrin we asked whether the
cells expressed VN when seeded on collagen. We found that in
defined serum free culture, negligible amounts of VN were
expressed (Figure S1A). In contrast fibronectin, another avb5
ligand, was expressed (Figure S1B). To understand how integrin
b5 could promote an increase in cell area and cell tension on
collagen we tested whether increased cellular integrin b5 levels
were detected as an increase in integrin b5 binding to collagen/
fibronectin as we found for b5 binding on VN by uPA silenced
cells (Figure 2G). HCFs were transfected with uPA siRNA or
control siRNA and seeded on collagen. After 24 hours in culture, a
reversible cross-linker was added. Cells were removed with 0.1%
SDS and proteins that were cross-linked to the matrix were
released. Equal amounts of released protein were Western blotted
for integrin b5 (Figure 6A, top). Although b5 binds to matrix
(collagen plus secreted fibronectin), the amount of b5 binding was
Figure 4. siRNA knockdown of uPA triggers incorporation of a-SMA into stress fibers. HCF were transfected with siRNA against uPA or
control siRNA and after 24 hours (A) cells were immunostained for a-SMA. Bar=10 um or 20 um. Images are from two independent experiments. (B)
Metamorph analysis quantified changes in average cell size in each condition. ***p value,0.001. (C) Cell lysates were Western blotted for a-SMA and
for uPA to confirm knock down. GAPDH indicates equal loading. Densitometry for a-SMA/GAPDH is shown. N=3–5 for each experiment.
doi:10.1371/journal.pone.0033915.g004
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cell-surface b5 is not directly responsible for promoting a Mf-like
phenotype on this collagen/fibronectin matrix. We next investi-
gated whether integrin b1 subunit, common to many collagen/
fibronectin binding integrins contributed to the adhesion and
enlarged cell morphology when HCFs were seeded on collagen
after uPA-silencing. Unlike integrin b5, we found significantly
increased matrix (collagen/fibronectin) binding by integrin b1
after uPA-silencing. These data are supported by our adhesion
assay in which initial adhesion of cells transfected with uPA siRNA
or control siRNA was tested. After 24 hrs, transfected cells were
resuspended and seeded in the presence of blocking antibodies for
1 hour. b5 blocking antibody did not block adhesion on collagen
but b1 blocking antibody resulted in a 58% percent decrease in
cell adhesion (Figure 6B). The effect of blocking antibodies was
identical to uPA-silenced cells for cells transfected with control
siRNA (data not shown). A second set of experiments tested the
impact of the integrin blocking antibodies on cell attachment after
overnight incubation with antibody to parallel the experiment
performed in Figure 5A. In this experiment, blocking antibody to
either b5o rb1 was added with cells immediately after transfection
with uPA siRNA or control siRNA. After 24 hours in culture, cells
were washed and adherent cells were quantified. As above, b5
blocking antibody did not alter cell adhesion, and b1 blocking
antibody treatment led to a 38% decrease in cell adhesion (Figure
S2A). The greater blocking that is observed after a 1 hour
treatment compared to blocking overnight is likely because
treatment overnight permits non-b1 cell adhesion molecules to
recover cell attachment. Consistent with a role for cell spreading,
treatment with blocking b1 antibody also resulted in a decrease in
cell size (of the remaining attached cells), which were devoid of
organized of a-SMA stress fibers that is typically visualized after
uPA-silencing (Figure S2B).
We next determined if the cell-surface levels of b1 were affected
by uPA-silencing. Using cell surface biotinylation, we found an
average 1.33 fold increase in the levels of cell-surface integrin b1
after uPA-silencing (Figure 6C). Unlike b5, this corresponded with
an average 1.25 fold increase in b1 gene expression (Figure 6D).
Figure 5. Treatment with anti-avb5 antibody reverses the effect of uPA-silencing. HCFs were transfected with uPA siRNA and seeded with
a blocking avb5 antibody or matched IgG. After 24 hours (A) cells were immunostained with anti-a-SMA antibody. Bar=10 um. Images are from two
independent experiments. (B) Metamorph analysis quantified changes in average cell size in each condition. ***p value,0.001. N=3 for each
experiment.
doi:10.1371/journal.pone.0033915.g005
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in which there was an average 1.24+/2.07 fold increase in
integrin b1 cell-surface levels, *p value,.05, after uPA-silencing
(Figure 6E). To determine if the increase in b1-collagen binding
correlated with a change in b1 activity, flow cytometry was
performed using the HUTS-4 antibody that detects the active
conformation of integrin b1. We demonstrate that after uPA-
silencing, active b1i sdecreased by an average 20%+/2.05%, *p
value,.05 (Figure 6F). To summarize, Figures 4, 5, and 6
demonstrate that when HCFs are plated on collagen, uPA-
silencing induces a Mf-like phenotype and an increase in cell-
surface b5, and that although b5 blocking antibody does not
detach cells it reverses the Mf-like phenotype, suggesting that
integrin b5 is affecting the activity of a b1 integrin.
Integrin b5 regulates integrin b1
To test if the increase in b5 cell-surface levels after uPA-
silencing altered integrin b1 activity, we incubated uPA-silenced
cells with b5 blocking antibody overnight as in Figure 5.
Again utilizing the matrix cross-linking assay (Figure 6A), we
demonstrate that treatment with avb5 blocking antibody reduces
integrin b1/matrix binding compared to control IgG (Figure 7A,
compare lanes 1 and 3) revealing that integrin b5 mediates b1/
matrix binding under these conditions. We also confirm the
finding in Figure 6A that uPA-silencing increases b1 binding to
matrix by demonstrating that there is increased b1 after uPA-
silencing compared to control siRNA when treated with control
IgG (Figure 7A, compare lanes 3 and 4). Flow cytometry was used
to demonstrate that b5 blocking antibody also increased b1
Figure 6. Cell-surface integrin b1 binding to collagen is increased after uPA-silencing but b1 activation is decreased. (A) HCFs were
transfected with uPA siRNA or control siRNA. After 24 hours HCF were crosslinked to collagen. After cells were removed with 0.1% SDS, matrix-bound
cross-linked proteins were released and equal amounts of protein were analyzed for integrins b5 and b1 by Western blot. (B) Cell adhesion: HCFs
were transfected with uPA siRNA. After 24 hours cells were detached and seeded with blocking antibody to b5, b1 or control IgG. After 1 hour,
adherent cells were quantified. **p value,0.01. (C–F) HCFs were transfected with either uPA siRNA or control siRNA and cells were analyzed after
24 hours. (C) Cell-surface biotinylation for integrin b1.(D) RT-PCR for uPA and integrin b1, *p value,0.05 and ***p value,0.001. (E) Flow cytometry for
integrin b1. (F) Flow cytometry for activated integrin b1. N=3–5 for each experiment.
doi:10.1371/journal.pone.0033915.g006
uPA Regulates Integrin avb5
PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e33915activation by 1.19+/2.04 fold, *p value,.05 (Figure 7B).
Together our data suggest that the increase in b5 cell-surface
levels after uPA-silencing promotes b1-mediated cell attachment
that correlates with a decrease in integrin b1 activity. Further-
more, this integrin b1-mediated cell attachment to the collagen/
fibronectin matrix results in increased cell spreading and a-SMA
organization.
Discussion
Since the persistence of Mfs in wounded tissue correlates with
fibrotic disease, uncovering mechanisms that promote Mf
differentiation is important to our fundamental understanding
and treatment of fibrosis. In the current study, we demonstrated
that the absence of uPA led to an increase in total and cell-surface
integrin b5, as a result of decreased degradation of internalized
avb5. The enhanced levels of integrin b5, increased integrin b1
binding to a collagen/fibronectin matrix, generating enlarged
cells, which had a-SMA organized into stress fibers.
Our working model
Our current working model is based on the biologically relevant
finding that uPAR is downregulated on Mfs [6]. We have utilized
uPA-silencing (and uPAR-silencing) to reveal potential uPA/
uPAR-based mechanisms that may be aberrant in fibrotic disease.
Here we show that there is a reciprocal relationship between uPA/
uPAR and avb5. Previous studies demonstrate that over-
expression of integrin avb5 promotes the Mf phenotype and high
levels of avb5 are found in fibrotic, sclerodermal tissue [14]. These
data together with our findings suggest that the downregulation of
uPA or uPAR or a change in uPA/uPAR binding could promote a
pathology-causing accumulation of integrin avb5 in vivo. This
hypothesis is supported by an in vivo study where in uPAR-deficient
mice dermal wound healing was fibrotic as characterized by
increased dermal thickness, collagen deposition, and Mf differen-
tiation [33]. Similarly, knocking out uPAR increased the
progression of liver fibrosis [34]. Although the observed increase
in collagen deposition in these studies is due at least in part to the
decreased cell-surface uPA activity, the mechanism responsible for
generating Mfs was not determined. Our model predicts that after
uPAR knockdown, an increase in integrin b5 contributes to the
generation of Mfs in healing wounds. Other studies of fibrotic
diseases have discovered alterations in the uPA/uPAR interaction.
These include a Scleroderma (SSc) study using vascular endothe-
lial cells in which uPAR expression is upregulated but uPAR is
cleaved, thus preventing uPA binding [35,36]. The authors
suggested that reduced uPA/uPAR binding inhibits tissue
vascularization leading to ischemia that is a hallmark of SSc.
Another study characterized the uPA/uPAR system on fibroblasts
from limited and diffuse types of SSc by comparing affected versus
non-affected skin in these patients. The ratio of uPA secretion to
uPAR expression was increased in the affected areas (1.4 fold for
limited SSc and 3.5 fold for diffuse) [37], again suggesting that a
change in uPA/uPAR binding is associated with fibrosis. Finally,
the importance of uPA/uPAR binding was highlighted in a study
in which endogenous uPA/uPAR binding was abrogated in a
mouse model, resulting in chronic inflammation secondary to
fibrin deposition, both of which are associated with fibrotic disease
[38,39].
Ubiquitination of integrins and integrin binding to ECM
Accumulation of specific matrix molecules is a hallmark of
fibrosis. Since integrins and ECM are internalized together [40],
the finding of reduced avb5 degradation suggests a parallel
reduced ECM degradation and increased recycling of non-
degraded integrin/ECM to the cell-surface. A recent study
reported that internalized a5b1 is ubiquitinated and targeted to
lysosomes for degradation and that fibronectin binding is
necessary for a5b1 ubiquitination and degradation of the
integrin/ECM complex [26]. The authors proposed that in the
absence of degradation, the integrin/ECM complex would be
recycled to the cell-surface, leading to an increase in cell
adhesion and a build-up of ECM, that would lead to stabilized
cell adhesion and reduced cell migration. Our data support this
model as decreased avb5 degradation led to an increase in the
cell-surface accumulation of integrin b5. When cells were seeded
on VN, the increase in integrin b5p r o m o t e db5/VN binding
and cell adhesion (2.4 fold increase) (Figure 2G). In addition, the
elevated cell-surface levels of integrin b5 promoted integrin b1/
collagen binding (Figures 6 and 7), resulting in enlarged cells and
organization of a-SMA containing stress fibers. Both VN and
collagen matrices include fibronectin secreted by HCFs even
under serum-free conditions (Figure S1). Since the in vivo fibrotic
matrix includes VN, collagen and fibronectin, it is possible that a
change in uPA/uPAR status that produces an increase in
integrin b5 cell-surface levels, could generate Mf-like cells on VN
directly and/or induce integrin b1 binding to a collagen/
fibronectin matrix. (Integrin cross-talk is discussed below.)
Furthermore, since VN and avb5 are internalized together
[41], we propose that the accumulation of avb5c o u l dl e a dt oa n
accumulation of VN in the ECM that is associated with fibrotic
healing [42].
Figure 7. b1 integrin is activated by blocking integrin b5. (A) HCFs were transfected with uPA siRNA or control siRNA and seeded with a
blocking avb5 antibody or matched IgG. After 24 hours HCF were crosslinked to collagen. The amount of b1 released from the matrix after cell
removal is visualized by Western blot. (B) HCFs were transfected with uPA siRNA. After 24 hours, cells were analyzed by flow cytometry for activated
integrin b1. N=3 for each experiment.
doi:10.1371/journal.pone.0033915.g007
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integrin b5, one possibility is that the binding of uPA to integrin
avb5 [31,32] may change the conformation and/or phosphory-
lation state of avb5 and make it accessible to ubiquitination.
Previous studies demonstrate that phosphorylation of integrins is
necessary for a wide range of integrin functions such as migration,
adhesion, and downstream signaling [43,44,45]. Furthermore,
dependence for ubiquitination on the phosphorylation state of the
focal adhesion component, talin has been described [46].
Alternatively, since the uPA inhibitor, PAI-1 stimulates the
internalization of uPA/uPAR with the LRP receptor and integrins
avb3 and avb5 [47,48], perhaps, avb5 internalization through an
uPA-mediated pathway is necessary for avb5 ubiquitination and
degradation.
Crosstalk between integrins
Crosstalk between integrins or between integrins and other
adhesive molecules such as cadherins, plays an important role in
controlling cellular activities such as cell migration, cell adhesion,
and ECM remodeling [49]. Specific to our data are studies
demonstrating crosstalk between avb5 and the collagen binding
integrin, a2b1, which report that a2b1 function (stimulation or
repression) is dependent on the levels of integrin avb5. Utilizing
human colon cancer cells lines, the authors found that cell-surface
avb5 repressed a2b1-mediated cell migration on collagen, which
could be overcome by treatment with a b1-activating antibody
(TS2/16). In contrast, blocking avb5 increased a2b1-mediated
cell migration (approximately 5-fold) and addition of b1 activating
antibody did not further increase cell migration, suggesting that
under conditions in which avb5 is blocked, b1 is maximally
activated [50]. These data correlate with our findings that high
levels of b5 increase b1 binding to collagen/fibronectin matrix
(stabilized cell adhesion, in line with reduced cell migration) with
reduced b1 activity (Figure 6), whereas blocking antibody to avb5
reduced b1 binding to this matrix and increased b1 activity (in line
with increased cell migration) (Figure 7). Future studies will define
which b1 integrin is activated by avb5 on Mfs. In addition to
a2b1, a11b1, has been demonstrated to be a key mechanical
sensor that influences Mf differentiation on collagen [51] and thus
it may be regulated by avb5.
Accumulation of avb5 and TGFb
Our data suggest that together, a TGFb-mediated increase in
b5 gene expression (Figure 1C) and a decrease of uPA/uPAR on
Mfs (Figure 1C and [6]), could lead to a pathology-promoting
accumulation of avb5 and could result in an avb5-mediated
autocrine loop of TGFb activation. Although, we did not observe
the expected increase in active TGFb after uPA-silencing (as
discussed in the results section), the profound changes in cell size
and the generation of a-SMA containing stress fibers, in cells that
had none, without observable differences in TGFb activity
revealed that these changes were not TGFb-dependent. Further-
more, the finding that a-SMA expression was not altered after
uPA-silencing (as would be expected without an increase in TGFb
activity) suggests that the change in cell size and incorporation of
a-SMA into stress fibers after uPA-silencing is primarily the result
of enhanced mechanical tension, which, in the presence of a-
SMA, generates its incorporation into stress fibers. These data are
consistent with reports that the generation of mechanical tension is
a key to the persistence of Mfs [11,51,52] and supports the idea
that although TGFb is a primary inducer of ECM accumulation
and fibrosis, that targeting adhesion molecules such as integrins, in
order to reduce persistent (adherent) Mfs may produce successful
anti-fibrotic therapies [53]. Towards this end, blocking the
epithelial specific avb6 integrin has proven successful in animal
models for reducing fibrotic disease [54,55].
Conclusion
In summary, uPA-silencing provides a useful model to study the
effects of increases in cell adhesion and mechanical tension that
lead to a-SMA stress fiber organization without invoking
additional effects of high levels of TGFb. Based on our data
potential therapeutic targets to combat fibrosis may be maintain-
ing uPA bound to uPAR on the cell-surface by preventing uPAR
cleavage. The downstream signaling that results from inhibiting
uPAR cleavage is under investigation [56,57]. In addition, directly
blocking integrin avb5 or targeting the ubiquitin pathway to
increase the rate of integrin avb5 degradation may generate new
therapies to reduce fibrotic healing.
Materials and Methods
Antibodies and reagents
Integrin b5 antibody for blocking and flow cytometry was from
R & D Systems (MAB2528). Integrin b5 antibody for Western blot
and IP (ab15459), uPA antibody (Western blot) (ab24121), and
GAPDH antibody (ab36845) were from Abcam. a-SMA antibody
(04–1094) and ubiquitin antibody (FK2) were from Millipore (04–
263). uPAR antibody (R3) (BPDMONR3) was from Enzo Life
Sciences. Integrin b1 antibody for flow cytometry was from R&D
Systems (MAB17781). Antibody to active form of b1 (HUTS-4,
MAB2079Z) was from Millipore. Secondary Alexa-488 and Alexa-
568 were from Molecular Probes, Eugene, Oregon. HRP-
conjugated anti-Streptavidin antibody and all HRP-conjugated
secondary antibodies were from Jackson Laboratories. Magnetic
Streptavidin beads were from Pierce. Human siRNAs to uPA
uPAR, tsg101, and hrs was from Santa Cruz Biotechnologies. The
non-targeting fluorescent nucleotide control (siGlo) was from
Dharmacon. Bovine Collagen type I (PureCol) was from Inamed.
a-2-anti-plasmin was from Abcam (ab77936). The uPAR mutant
construct (non-cleavable uPAR) was a generous gift of Dr. Lilliana
Ossowski, Mount Sinai School of Medicine, NY, NY. The
construction of this vector was described previously [22].
Cells and media
Human primary corneal fibroblasts (HCF) were derived from
the stroma of human corneas that were not suitable for
transplantation (obtained from NDRI, Pittsburgh, PA). Stromal
fibroblasts were isolated as previously described [6] and main-
tained in complete media: DMEM-F12 (Invitrogen) with 10% FBS
(Atlanta Biologicals) with ABAM and Gentamicin (Sigma). For
experiments except where noted cells were plated on 10 ug/ml
collagen in supplemented serum-free media (SSFM): DMEM-F12
plus 16 RPMI-1640 Vitamin Mix, 16 ITS Liquid media
supplement, 1 mg/ml glutathione; (all from Sigma), 2 mM L-
glutamine, 1 mM sodium pyruvate, 0.1 mM MEM non-essential
amino acids; (Invitrogen) with ABAM and Gentamicin.
Immunocytochemistry
Cells were fixed with 3% p-formaldehyde (Fisher Scientific, Fair
Lawn, NJ) and permeabilized with 0.1% Triton X-100 (Sigma).
After blocking with 3% normal mouse serum (Jackson Immuno
Research), cells were incubated with a-SMA antibody and then
secondary antibody labeled with Cy3. Coverslips were viewed with
a Zeiss Axioskop microscope and images were captured using a
Zeiss Axioscope with a SPOT-2 CCD camera (Diagnostic
Instruments, Sterling Heights, Michigan) and processed by Adobe
PhotoShop software.
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Cells were lysed in Triton buffer (1% Triton, 150 mM NaCl,
20 mM Tris, pH 7.5) plus complete protease inhibitor tablet
(Roche) and PMSF (Fisher Scientific). 30 mg of protein was
separated on 4–12% NuPAGE gradient gels under reducing
conditions (b5, a-SMA, and GAPDH), or non-reducing (uPAR
and uPA), and transferred to PVDF membranes. Primary
antibody was added to 5% BSA in TBS and secondary antibody
was added to 1% milk in TBS. Bands were visualized with ECL
(Pierce).
Blocking avb5 with antibody
HCF were seeded on collagen in SSFM and grown for 48 hours
with 1 ng/m TGFb1 before addition of 2.5 ug/ml anti-avb5
function blocking antibodies or IgG controls for 24 hours
(Figure 1). To block avb5 after uPA siRNA transfection, 2.5 ug/
ml anti-avb5 or matched IgG was added to the transfected cells
before seeding on collagen in SSFM (Figure 5).
Transfections
Transient transfection was performed using the Amaxa
NucleofectionH system (Gaithersburg, MD). HCFs were transfect-
ed using the NHDF kit with 10 mM of human targeting uPA or
uPAR siRNA or 10 mM control siRNA (siGLO) and seeded on
collagen in SSFM without antibiotics. Cells were analyzed after
24 hours. For ESCRT protein knockdown, 10 mM hrs plus 75 mM
tsg101 [26] were transfected and compared to 85 mM siGLO.
Cells were lysed for Western blot after 48 hours. Knockdowns
were confirmed by Western blot and RT-PCR. For the over-
expression of non-cleavable uPAR, HCF were transfected with
2.0 mg human NC-uPAR cDNA, or control pcDNA in 10% FBS
and F12-DMEM without antibiotics. The next day media was
changed to SSFM and the following day cells were lysed for
Western blotting, or uPA assay (Figure 2). Over-expression was
confirmed by RT-PCR. Transfection efficiency (approximately
80%) was monitored by separately expressing EGFP.
PA activity assay
This assay was performed as previously described [6]. Briefly,
cells were plated onto collagen in SSFM experiments were
performed as described above. Cells were lysed in 0.1% Triton-X-
100 in 100 mM Tris pH 8.0. After equalizing protein concentra-
tions, uPA activity was determined by incubation with 2 ug of
plasminogen and generation of plasmin was determined using a
chromogenic plasmin substrate (Spectrozyme PL, American
Diagnostic). The reaction product was measured on a Biotek
spectrophotometer (A405 nm) at 1 hour.
Plasmin activity inhibition
HCFs were transfected with 2.0 mg human non-cleavable uPAR
cDNA, or control pcDNA in 10% FBS and F12-DMEM without
antibiotics. The next day media was changed to SSFM and either
not treated or treated with 10 ug/ml a-2-anti-plasmin for
24 hours before lysing with Triton buffer plus inhibitors.
RNA extraction and real time PCR
TotalRNAwasextractedfromcelllysatesusingtheTRIReagent
RT kit (MRC, Cincinnati, OH) and cleaned by RNeasy Mini Elute
Cleanup Kit (Qiagen, Valencia, CA). First stranded cDNA was
generated from1 mgoftotalRNAusingtheSuperscript FirstStrand
and oligo dT (Invitrogen) according to the manufacturer’s
instructions. Absolute Blue qPCR master mix (Fisher) was used to
generate PCR product. Triplicate determinations were analyzed
using the ABI 7900 sequence detection system. Annealing
temperature was 55uC for all reactions. Primers used were b5
(IDT):CTGTCCATGAAGGATGACTT, TGTCCACTCTGT-
CTGTGAGA; b3(IDT):GTAGCCAAACATGGGCAAGC, TC-
ACCAGTAACCTGCGGATTG; uPAR(Invitrogen): CTGGA-
GCTGGTGGAGAAAAG, GCTTCGGGAATAGGTGACAG;
GAPDH (Invitrogen):TTGATTTTGGAGGGATCTCG, GAGT-
CAACGGATTTGGTCGT; uPA (Invitrogen) GGGGAGATG-
AAGTTTGAGGT, CTCTTTTCCAAAGCCAGTGA. Integrin
b1(IDT); CCTTCTATTGCTCACCTTGTCC, ACTTGGGAC-
TTTCAGGGATG, Tsg101(IDT);GGACACATACCCATATA-
ATCCCC, TCATCCGCCATCTCAGTTTG, Hrs (IDT); AG-
GAGAAGGAGAGGCTGAG, TGTGGTTACTCTTCATGC-
GG; Vitronectin (IDT); TGCTGGCATGGGTTGCT, GTT-
CATGGACAGTGGCATTGTT; Fibronectin (IDT); TGATCA-
CATGGACGCCTGC, GAGTCAAGCGGACACAACG.
Immunoprecipitation (IP)
Figure 1A: Cells were treated for 72 hours with either 1 ng/ml
TGFb1 or 5 ng/ml FGF-2 with 1 ug/ml heparin in SSFM on
collagen. For cell-surface expression, cells were biotinylated for
30 minutes with 0.5 mg/ml EZ-Link Sulfo-NHS-LC-Biotin
(Pierce). Cells were lysed in Triton Buffer plus protease inhibitors.
For each IP, 5 ug of b5 antibody were added to 0.5 mg of total
protein and incubated overnight at 4uC. Eluted proteins were
separated under reducing conditions. Western blots were pro-
cessed in 5% BSA in TBS and incubated with streptavidin-HRP.
Bands were visualized with ECL (Pierce). Figure 2F: HCFs were
transfected with either uPA siRNA or control siRNA. After
24 hours cells were biotinylation as above. Cell lysis in RIPA
buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 0.1% SDS, 0.5%
Sodium Deoxycholate, 1% Triton) plus inhibitors. Biotinylated
proteins were precipitated using streptavidin coated magnet beads
(MagnaBind, Thermo Scientific). The proteins were eluted under
reducing conditions and Western Blotted for integrin b5.
Figure 3E: HCFs were transfected with either uPA siRNA or
control siRNA. After 24 hours cells were lysed with RIPA plus
protease inhibitors, IPed with antibody to ubiquitin (FK2) and
immunoprecipitates were Western blotted for b5.
Adhesion Assay
Figure 2G: HCF were transfected with either uPA siRNA or
control siRNA as above. The next day, cells were resuspended
with Detachment buffer (enzyme-free cell dissociation solution,
Millipore) and 20,000 cells were seeded in SSFM into vitronectin-
coated wells (2 ug/ml). After 24 hours, the cells were fixed with
3% paraformaldehyde and stained with DAPI. Three photos were
taken from different areas for each well. The imaged cells were
counted automatically using ImageJ ‘‘Analyze Particles’’ (particle
size were set from 20 to infinity). The numbers of 3 photos from
each well were averaged as the final number for that well. 6 wells
were analyzed for each transfection. Figure 6B: HCF were
transfected with uPA siRNA or control siRNA. After 24 hours,
cells were detached with detachment buffer and seeded onto
collagen in a 96 well plate with blocking antibodies: 1.25 ug/mL
b5 antibody, 1.25 ug/mL b1 antibody or 1.25 ug/mL control
IgG. After 1 hour cells were washed with PBS thoroughly with
tapping and fixed by methanol and stained with 0.1% crystal violet
for 1 hour at room temperature. Crystal violet was eluted with
10% acetic acid and the eluate was measured at 570 nm. Figure
S2A: HCF were transfected with uPA siRNA or control siRNA
and 25,000 cells were seeded onto collagen in 96-well plates with
blocking antibodies: 1.25 ug/mL b5 antibody, 1.25 ug/mL b1
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washed and stained with cystal violet and measured as above.
Cross-linking Assay
HCF were transfected with uPA siRNA and control siRNA.
Cells were seeded on collagen in SSFM on a 100 mm dish. The
next day cells and matrix were cross-linked by 1 mM BSOCOES
(Thermo Scientific) for 10 minutes, and then quenched twice with
a buffer containing (50 mM Tris-HCl (pH 7.2) and 100 mM
NaCl). The cells were then removed by lysis with 0.1% SDS with
protease inhibitors and the plates were washed three times with
PBS. After washing, the plates were incubated in 50 mM
NaHCO3 (pH 11.6) and 0.1% SDS with protease inhibitors at
37uC with shaking for 2 hours to reverse cross-linking. The soluble
fraction was concentrated by Amicon Ultra (Millipore) and stored
at 280uC. Equal protein from each sample was analyzed by
Western blotting. A lack of GAPDH on Western blots confirmed
that cells were not present in the protein fraction that was released
from the matrix.
Internalization Assay
Our method was based on the paper by Vassilieva et al. [58].
HCFs were transfected and cell-surface proteins were biotinylated
as above. Labeled cells were gently washed three times in cold PBS
and then incubated at 37uC in SSFM for 30 minutes. Biotin
remaining on the cell-surface was cleaved with buffer containing
reducing agent [100 mM MESNA (sodium-2-mercaptoethane
sulfonate), 50 mM Tris (pH 8.6), 100 mM NaCl, 1 mM EDTA,
and 0.2% BSA] at 4uC (3 washes). The cells were rinsed twice in
ice-cold PBS, and excess biotin was quenched with 60 mM
iodoacetamide in PBS for 5 min at 4uC. Cells were then washed
three times in ice-cold PBS and lysed in RIPA buffer plus
inhibitors. The lysates were clarified by centrifugation at 14,000 g
for 10 min. Biotinylated proteins were precipitated using strepta-
vidin coated magnet beads. The proteins were eluted under
reducing conditions and Western Blotted for integrin b5.
Degradation Assay
HCFs were transfected and cell-surface proteins were biotiny-
lated as above. Labeled cells were gently washed twice in cold
PBS. Cells were returned to 37uC and at the specified time points
(0, 1, 6, 24 hours) cells were quenched by 100 mM glycine and
lysed by RIPA buffer plus inhibitors. Biotinylated proteins were
precipitated using streptavidin coated magnet beads. The proteins
were eluted under reducing conditions and then Western blotted
for integrin b5. (Since the cells were incubated for 24 hrs after
biotin labeling, to avoid additional perturbation of the cell culture,
the cleaving of biotin as in the internalization assay was omitted.)
Flow cytometry: Detection of Integrin b5, b1 and active
b1
Integrin b5: HCFs were treated with primary antibody (R & D
systems) at 1.25 ug/mL at 4uC. After 1 hr, cells were washed by
PBS three times, then detached by enzyme-free cell dissociation
solution (Millipore) and resuspended in PBS with 3% BSA. 4610
5
cells/400 ul were removed and incubated with goat anti-mouse
Alexa-488 (1:400, Jackson ImmunoResearch) for 30 min at 4uC.
The cells were then washed twice by PBS with 3% BSA and
filtered into a 5 mL polystyrene tube with cell-strainer cape (BD
Falcon). After being stained by propidium iodide, the cells were
analyzed by Accuri C6 flow cytometer. Integrin b1 (cell-surface or
active): Cells were detached by enzyme-free cell dissociation
solution (Millipore) and resuspended in DMEM with 3% BSA.
1610
5 cells/100 ul were removed and incubated with antibody
against integrin b1 (2.5 mg/10
5 cells) or active integrin b1( 5mg/
10
5 cells) for 30 min at 4uC prior to washing and incubated with
goat anti-mouse Alexa-488 (1:400, Jackson ImmunoResearch) for
30 min at 4uC. Cells were washed and counted as above. Negative
control is the omission of primary antibody in each case. Average
fold change between samples is calculated by first subtracting the
negative from each sample before averaging the mean fluores-
cence of the experimental samples and the control samples. The
fold change is the average of the mean fluorescence of the
experimental samples divided by the average of the control
samples. Standard error and p values are given for each set of
experiments.
Statistical Analysis
Numerical data are expressed as the mean +/2 standard error
of 3 to 7 independent experiments. P-values were calculated using
the students t-test. *p value,0.05, **p value,0.01, ***p
value,0.001.
Supporting Information
Figure S1 HCFs under defined conditions, express
fibronectin but not vitronectin. HCFs were transfected with
uPA siRNA or control siRNA. After 24 hours RNA was extracted
for RT-PCR. (A) vitronectin and (B) fibronectin. No statistically
significant changes were demonstrated between samples in either
case. The data is not converted into percent to demonstrate that
VN is nearly undetectable in HCFs under serum-free contiditons
compared to fibronectin. N=3 for each experiment.
(TIF)
Figure S2 Antibody to b1 but not b5 blocks cell adhesion.
(A) Cell adhesion: HCFs were transfected with uPA siRNA and
seeded with blocking antibody to b5, b1 or control IgG. After
24 hours adherent cells were quantified. **p value,0.01. (B)
HCFs were transfected with uPA siRNA or control siRNA and
seeded with 2.5 ug/ml blocking anti-b1 antibody or control IgG.
Bar=10 um. Cells were immunostained for a-SMA. N=3 for
each experiment.
(TIF)
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